# Toceranib phosphate

Source: https://onco.cc/drugs/toceranib/  
OnCo record `toceranib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Toceranib (Palladia) is a tablet for dogs, not people, approved by the US Food and Drug Administration in 2009 to treat mast cell tumours of the skin that have come back. It blocks the same family of growth signals as the human cancer drug sunitinib.

## Summary

Palladia (toceranib phosphate) tablets were approved by the FDA Center for Veterinary Medicine on 22 May 2009 under NADA 141-295, for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs; the sponsor was Pharmacia & Upjohn Company, a division of Pfizer, and the current label names Zoetis as distributor.

The pivotal study was a multicentre, placebo-controlled, double-blind trial in dogs with recurrent mast cell tumours after surgery (London et al., Clin Cancer Res 2009). In the six-week blinded phase the objective response rate was 37.2% with toceranib (86 dogs) against 7.9% with placebo (63 dogs). The label describes toceranib as an inhibitor of VEGFR2, PDGFR and KIT (the trial report names PDGFRB), the receptors that the human drug sunitinib also blocks; it was developed under the code SU11654. It is a veterinary medicine and has no human approval.

## Fields

- Kind: Treatment
- Last checked: 2026-11-04
- Also known as: Palladia; toceranib; SU11654
- Tags: veterinary; comparative-oncology
- Brand: Palladia
- Code: SU11654
- Modality: small molecule (kinase inhibitor)
- Mechanism: An oral inhibitor of split-kinase receptor tyrosine kinases; the label states it inhibits Flk-1/KDR (VEGFR2), PDGFR and the stem cell factor receptor KIT, and canine mast cell tumours are frequently driven by activating KIT mutations.

## Sources

- FDA Consumer Update: My Dog Has Cancer: What Do I Need to Know?: https://www.fda.gov/consumers/consumer-updates/my-dog-has-cancer-what-do-i-need-know
- FDA Freedom of Information Summary, NADA 141-295 Palladia (approved 22 May 2009): https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/860
- Palladia package insert (Animal Drugs @ FDA): https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/888
- London et al. 2009, Clin Cancer Res: randomised placebo-controlled study of toceranib in canine mast cell tumour: https://doi.org/10.1158/1078-0432.ccr-08-1860

## Connected records

- ideas: [Pet dogs with spontaneous cancer as a bridge before human trials](https://onco.cc/ideas/idea-bio1-comparative-oncology-dogs/)
- journals: [Veterinary and comparative oncology](https://onco.cc/journals/veterinary-and-comparative-oncology/)
- drugs: [Sunitinib](https://onco.cc/drugs/sunitinib/)
- targets: [KIT](https://onco.cc/targets/kit/), [PDGFRB](https://onco.cc/targets/pdgfrb/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/toceranib.json